Appeal No. 98-1012
Serial No. 08/117,342
DISCUSSION
2
Enablement
The crux of examiner=s position is that claim 5 does not recite
the concentration at which Cefsulodin suppresses non-coliform
bacteria but not coliform bacteria. Furthermore, the
specification does not provide the necessary information to
determine the appropriate level for achieving that result.
In considering this issue, we note that appellants are
not required to disclose every concentration encompassed by
the
claims. See In re Angstadt, 537 F.2d 498, 190 USPQ 214 (CCPA
1976). However, there must be sufficient disclosure, either
through illustrative examples or terminology to teach those of
ordinary skill in the art how to make and use the invention as
broadly as it is claimed. See In re Vaeck, 947 F.2d 488, 20
11
Page: Previous 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next
Last modified: November 3, 2007